Latest total assets for PLX: $100M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Protalix BioTherapeutics (PLX) currently reports a total assets of $100M as of March 2026. That compares with $74M in the prior-year period — up 38.5% year over year. Use the charts on this page to explore Protalix BioTherapeutics's total assets history and peer comparisons.
Protalix BioTherapeutics's total assets increased from $74M to $100M — a 38.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Protalix BioTherapeutics reported $100M in total assets as of March 2026. That compares with $74M in the prior-year period — up 38.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total assets of $100M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Protalix BioTherapeutics, and consider following PLX for alerts when major investors trade the stock.
Protalix BioTherapeutics is classified in the Healthcare sector. On total assets, it currently shows $100M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLX with unrelated industries.